

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES.

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Stockholm, Sweden, April 21, 2026. The Board of Directors of Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) has resolved on a directed share issue of in total 66,666,667 new ordinary shares at a subscription price of SEK 5.25 per share, corresponding to the closing price on Nasdaq Stockholm on April 21, 2026 (the “Directed Issue”), through which the Company receives SEK 350 million (approximately USD 38 million) before transaction costs. The Directed Issue was oversubscribed and included participation from new and existing investors, including U.S. biotech investors Frazier Life Sciences, Invus, Woodline Partners and Parkman Healthcare Partners, as well as Swedish biotech and long-only investors Linc AB, The Fourth Swedish National Pension Fund, Cidro Förvaltning AB (Peter Lindell), Unionen and other institutional investors.

Nicklas Westerholm, CEO of Egetis, commented: *“MCT8 deficiency is a rare, devastating, life-shortening disorder with no approved treatment in the U.S. We are very pleased to have concluded this successful fundraising, which has been supported by both existing and new shareholders. We are now well placed to execute on our strategy of progressing our lead asset Emcitate® (tiratricol) through U.S. approval and launch, helping us deliver Emcitate to patients affected by this rare genetic disease.”*

The Board of Directors of Egetis has, as announced in the press release from the Company today, resolved on a directed share issue of in total 66,666,667 new ordinary shares at a subscription price of SEK 5.25 per share, consequently raising proceeds of SEK 350 million (approximately USD 38 million) before transaction costs. The new ordinary shares will be issued based on the authorization granted by the annual general meeting on April 14, 2026.

The subscription price in the Directed Issue was determined through an accelerated bookbuilding procedure led by Stifel as Sole Global Coordinator and, together with Van Lanschot Kempen and DNB Carnegie, as Joint Bookrunners, and was, accordingly, in the assessment of the Board of Directors set on market terms and conditions.

The Company intends to use the proceeds from the Directed Issue to primarily finance:

- i. the preparation of Emcitate® (tiratricol) commercialization in the U.S., including completing the build-up of the commercial and medical affairs infrastructure;
- ii. the preparation of indication expansion into Resistance to Thyroid Hormone type beta (RTH-beta); and
- iii. working capital and general corporate purposes.

The Company estimates that the net proceeds from the Directed Issue will be sufficient to meet the following key milestones, which are based on current assumptions and expectations and may not be achieved within the anticipated timeframes, or at all:

- i. Emcitate U.S. FDA decision date (PDUFA date) for the review of the New Drug Application (NDA) for Emcitate (September 28, 2026);
- ii. Emcitate Priority Review Voucher subsequent issuance, if Emcitate is approved: September 28, 2026 or shortly thereafter. PRV monetization expected in Q4 2026; and
- iii. Emcitate U.S. launch: expected in Q4 2026.

The Board of Directors of the Company deems, after an overall assessment and careful consideration, that a new share issue with deviation from the shareholders' preferential rights is a better alternative for the Company's shareholders than a rights issue. A rights issue would entail significantly longer execution time and thereby increased market exposure and a higher potential risk of materially affecting the share price negatively, particularly in this volatile and challenging market, compared to a directed share issue. The cost of carrying out a directed share issue is deemed to be lower than in a rights issue. In addition, unlike a rights issue, the Directed Issue has broadened the shareholder base and provided the Company with new reputable institutional investors, which the Board of Directors believes will strengthen the liquidity of the shares and be beneficial to the Company.

The Directed Issue entails a dilution of approximately 13.7 percent of the number of shares and approximately 14.3 percent of the number of votes in the Company (calculated as the number of newly issued ordinary shares divided by the total number of shares and votes, respectively, in the Company after the Directed Issue). Through the Directed Issue, the total number of shares in the Company will increase by 66,666,667, from 424,161,938 to 490,828,605, of which 461,829,339 will be ordinary shares and 28,999,266 will be class C shares. The number of votes in the Company will increase by 66,666,667, from 398,062,598.6 to 464,729,265.6. The share capital will increase by approximately SEK 3,508,773 from approximately SEK 22,324,321 to approximately SEK 25,833,094.

In connection with the Directed Issue, the Company has agreed to a lock-up undertaking, with customary exceptions, on future share issuances for a period of 90 days after the settlement date of the Directed Issue. In addition, the shareholding members of the Board of Directors and members of the senior management have undertaken not to, subject to customary exceptions, divest any shares in the Company for a period of 90 days from the settlement date of the Directed Issue.

Advisers

Stifel acted as Sole Global Coordinator and, together with Van Lanschot Kempen and DNB Carnegie, as Joint Bookrunners in connection with the Directed Issue. Advokatfirman Vinge KB acted as legal adviser to the Company and Baker McKenzie acted as legal adviser to the Sole Global Coordinator and Joint Bookrunners in connection with the Directed Issue. Davis Polk & Wardwell LLP acted as U.S. legal adviser to the Company.

Important Information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Egetis in any jurisdiction.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by the Sole Global Coordinator and Joint Bookrunners. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This announcement does not constitute a recommendation concerning any investor's option with respect to the Directed Issue. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. The Sole Global Coordinator and Joint Bookrunners are

acting for the Company in connection with the Directed Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Directed Issue or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States of America, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, South Africa, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. Egetis has not authorized any offer to the public of shares or other securities in any member state of the EEA. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, "qualified investors" (as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024, as amended), who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) other persons to whom this document may be lawfully communicated (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as

of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq Stockholm rule book for issuers.

Information to distributors in the EEA

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Egetis have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "**EU Target Market Assessment**").

Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Egetis shares may decline and investors could lose all or part of their investment; the shares in Egetis offer no guaranteed income and no capital protection; and an investment in the shares in Egetis is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal, or regulatory selling restrictions in relation to the Directed Issue. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, the Sole Global Coordinator and Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Egetis.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Egetis and determining appropriate distribution channels.

Information to distributors in the United Kingdom

Solely for the purposes of the product governance requirements contained within: (a) Regulation (EU) 600/2014 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("**UK MiFIR**"); and (b) the FCA Handbook Product Intervention and Product Governance Sourcebook, (together, the "**UK MiFIR Product Governance Rules**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK MiFIR Product Governance Rules) may otherwise have with respect thereto, the shares in Egetis have been subject to a product approval process, which has determined that such shares are: (a) compatible with an end target market of retail investors and investors who meet the criteria of eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in UK MiFIR; and (b) eligible for distribution through all distribution channels as are permitted by UK MiFIR (the "**UK Target Market Assessment**").

Notwithstanding the UK Target Market Assessment, distributors should note that: the price of the shares in Egetis may decline and investors could lose all or part of their investment; the shares in Egetis offer no guaranteed income and no capital protection; and an investment in the shares in Egetis is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The UK

Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment, the Sole Global Coordinator and Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the UK Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of the UK MiFIR Product Governance Rules; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Egetis.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Egetis and determining appropriate distribution channels.

Foreign direct investment regulatory considerations

The Company is subject to regulation under the Swedish Foreign Direct Investment Act (*Sw. lagen (2023:560) om granskning av utländska direktinvesteringar*). Investors should note that the acquisition of shares and the crossing of certain thresholds may, under certain circumstances, trigger notification and/or approval requirements with the Swedish Inspectorate for Strategic Products (*Sw. Inspektionen för Strategiska Produkter*). Investors should make their own assessment of whether a notification obligation exists before making any investment decision.

For further information, please contact

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com
+46 (0) 733 542 062

Yilmaz Mahshid, CFO
yilmaz.mahshid@egetis.com
+46 (0) 722 316 800

Karl Hård, Head of Investor Relations & Business Development
karl.hard@egetis.com
+46 (0) 733 011 944

This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-21 22:57 CEST.

Attachments

[Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million \(approximately USD 38 million\)](#)